Back to News
Jun 8, 2026 4:00 PM

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

DexCom Inc. (NASDAQ:DXCM) stock is trading higher on Monday after the diabetes management company reported positive results from its CONNECT randomized controlled trial.

On Saturday, the study showed that use of the Dexcom G7 continuous glucose monitoring (CGM) system led to clinically and statistically significant reductions in A1C and improved glucose control among adults with Type 2 diabetes who are not using insulin.

Researchers also observed additional A1C reductions when Dexcom G7 was used alongside standard diabetes treatments, including metformin, GLP-1 therapies, and SGLT2 inhibitors.

Read Also:

Diabetes Tech Player DexCom Lays Out 2030 Growth Vision

Key Findings From The CONNECT Trial

Participants using Dexcom G7 recorded an average A1C reduction of 1.6% from ...